Abstract
The mood was upbeat at the International Neuromodulation Society meeting in Berlin in June with the news of St. Jude Medical’s investment in Spinal Modulation. In an industry beset by misfortunes, from failed clinical trials to lengthy approval cycles, to tighter capital availability, any kind of good news was welcome to investors, start-up companies, and established players alike.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
